Skip to main content
. Author manuscript; available in PMC: 2016 Aug 15.
Published in final edited form as: J Neuroimmunol. 2015 May 28;285:101–105. doi: 10.1016/j.jneuroim.2015.05.024

Table 3.

Percentage of Th1(+) and Th17(+) animals 1 month after MCAO.

Th1 response in: spleen lymph node ischemic hemisphere non-ischemic hemisphere
rMBP 17/37 (46%) 15/36 (42%) 7/22 (32%) 7/21 (33%)
MBP 68-86 16/37 (43%) 11/37 (30%) 12/22 (54%) 12/22 (54%)
MBP 63-81 14/37 (38%) 19/37 (51%) 6/22 (27%) 13/22 (59%)
bMBP 17/36 (47%) 13/34 (38%) 9/21 (43%) 12/21 (57%)
hMBP 19/37 (51%) 9/37 (24%) 4/22 (18%) 7/22 (32%)
OVA 16/37 (43%) 8/30 (27%) 10/22 (45%) 13/22 (59%)
Th17 response in: spleen lymph node ischemic hemisphere non-ischemic hemisphere
rMBP 19/37 (51%) 10/35 (29%) 6/22 (27%) 5/22 (23%)
MBP 68-86 11/37 (30%) 8/35 (23%) 7/22 (32%) 8/22 (36%)
MBP 63-81 14/37 (38%) 17/36 (47%) 8/22 (36%) 5/22 (23%)
bMBP 18/36 (50%) 12/33 (36%) 8/21 (38%) 9/21 (43%)
hMBP 19/37 (51%) 12/35 (34%) 7/22 (32%) 7/22 (32%)
OVA 10/37 (27%) 7/28 (25%) 11/22 (50%) 11/22 (50%)

Note: In a subset of animals undergoing MCAO (N=15), brains were removed and frozen. Lymphocytes were thus not available from these brains. rMBP=rat MBP, bMBP=bovine MBP, hMBP=human MBP, OVA=ovalbumin, MCAO=middle cerebral artery occlusion